Mangoceuticals, Inc. Names Award Winning Globally Recognized Lucky Break PR as Public Relations Firm

Rhea-AI Summary

Mangoceuticals, Inc. has announced Lucky Break Public Relations as its new PR Agency. The partnership aims to increase brand awareness and support marketing campaigns for MangoRx's men's health products, including its erectile dysfunction drug. Lucky Break will focus on corporate communications and expanding the brand's presence through sponsorship relationships and the upcoming launch of a new product.

Positive

• Mangoceuticals, Inc. partners with Lucky Break Public Relations to increase brand awareness and support marketing campaigns for its men's health products, including an erectile dysfunction drug. The partnership aims to expand the brand's presence through sponsorship relationships and the launch of a new product.

Negative

• None.

Dallas, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug branded “Mango,” is excited to announce that it names the Award Winning Globally Recognized Lucky Break Public Relations as its new PR Agency. MangoRx’s account will be managed by Lucky Break’s Health & Wellness division, a national communication team in charge of the agency’s portfolio of pharmaceutical, medical, health and fitness brands.

“We are very excited and extremely fortunate to be working with Lucky Break and their highly skilled team of public relations, marketing and branding specialists,” commented Jacob Cohen, CEO and Co-Founder of Mangoceuticals, Inc. “We believe as the Company seeks to aggressively increase its marketing and awareness campaigns, that working with a public relations firm such as Lucky Break who has experience working with other major global brands provides MangoRX with the additional support we need to further grow and expand our brand in becoming a household name.”

Lucky Break will focus on supporting corporate communications with a focus on increasing brand awareness around existing and soon-to-launch products while supporting MangoRx’s eye-catching marketing campaigns aimed at encouraging positive conversations around full “erectile function”.

“We believe MangoRx has best in class products and can quickly become the leaders in this space. Their existing and new products in development provide solutions for men seeking to improve their performance, vitality, and ultimately their quality of life. We are excited to play a part in their growth” said Lucky Break Principal, Mike Stommel. “The team at MangoRx is driven by innovation and have created a brand where humor drives conversation around improved intimacy potentially benefiting millions of men nationwide.”

MangoRx has recently commenced expanding its marketing footprint, in part with its recent sponsorship relationships with leading social media and podcast brands focused on the men’s demographic, such as Barstool Sports, Only Stans, Pillow Talk and No Jumper, as well as the nationwide launch of its “Make America Hard Again” (www.MakeAmericaHardAgain.com) campaign. With the upcoming launch of the Company’s new sildenafil-based Mango ED product, which contains the active ingredient found in Viagra^™ and other products to follow, Lucky Break will play a key role in the MangoRx global brand awareness and corporate communications.

About Lucky Break Public Relations

Founded in 2010, Lucky Break Public Relations is a full-service public relations, strategic marketing, and digital media agency representing clients in consumer products, health, wellness, pharmaceutical, sports & entertainment, non-profit, hospitality, food & beverage, architecture, design & development, and diversity marketing worldwide. Lucky Break helps craft and tell clients’ stories through creative development, earned media, social media, online presence, and real experiences. A globally recognized and award-winning communications firm, Lucky Break is headquartered in Los Angeles with offices in Washington, D.C., Austin, and New York. https://www.luckybreakpr.com

About Mango

Created using a special formulation featuring the same active ingredient as in Cialis^™ (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.

Mango is a prescription medication that must be approved by a physician. After an individual has completed an online tele-health visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.

About Mangoceuticals

Mangoceuticals, Inc. is a company focused on developing, marketing, and selling a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name "Mango" (think: "Man, Go!").

For more information, please visit www.MangoRx.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen and President, Jonathan Arango, combined have majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended June 30, 2023. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

Or just click here to see why Orange is the new Blue:
https://www.mangorx.com

FOR PUBLIC RELATIONS
Lucky Break Public Relations
Sahra Simpson
Sahra@luckybreakpr.com
(323) 602-0091 ext. 704

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com

SOURCE: Mangoceuticals Inc.

FAQ

Who is Mangoceuticals, Inc.'s new PR Agency?

Lucky Break Public Relations.

What is the focus of the partnership between Mangoceuticals and Lucky Break?

The partnership aims to increase brand awareness and support marketing campaigns for MangoRx's men's health products.

What is MangoRx's upcoming product launch?

MangoRx is launching a new sildenafil-based erectile dysfunction drug.

What are some of the sponsorship relationships MangoRx has established?

MangoRx has sponsorship relationships with leading social media and podcast brands focused on the men's demographic, such as Barstool Sports, Only Stans, Pillow Talk, and No Jumper.

What is the goal of MangoRx's marketing campaigns?

The goal is to encourage positive conversations around full 'erectile function' and improve brand awareness.